Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thereby taking advantage of the best characteristics of both components. Along with the development of the mAbs and cytotoxins, the design of chemical linkers to covalently bind these building blocks is making rapid progress but remains challenging. Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.

[1]  W. Denny,et al.  Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. , 2005, Journal of medicinal chemistry.

[2]  G. Bringmann,et al.  Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins. , 2007, Chemistry.

[3]  A. Mountain,et al.  A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. , 2005, Bioconjugate chemistry.

[4]  U. Zangemeister‐Wittke.  Antibodies for Targeted Cancer Therapy – Technical Aspects and Clinical Perspectives , 2006, Pathobiology.

[5]  S. Horning,et al.  Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Chari.  Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[7]  P. Trail,et al.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.

[8]  Damon L. Meyer,et al.  Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. , 2006, Bioconjugate chemistry.

[9]  L. Tietze,et al.  Synthesis and Biological Evaluation of Novel Analogues and Prodrugs of the Cytotoxic Antibiotic CC-1065 for Selective Cancer Therapy , 2002 .

[10]  M. Sliwkowski,et al.  Perspectives on Anti-HER Monoclonal Antibodies , 2002, Oncology.

[11]  I. Bernstein,et al.  Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.

[12]  Damon L. Meyer,et al.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.

[13]  M. Birkner,et al.  A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Bernstein,et al.  An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.

[15]  Hongsheng Xie,et al.  Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  Peter D. Senter,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003 .

[17]  G. Frantz,et al.  Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. , 2009, Cancer research.

[18]  P. Trail,et al.  Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.

[19]  N. Damle,et al.  Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma , 2006, Clinical Cancer Research.

[20]  D. Kroll,et al.  Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. , 2009, Bioconjugate chemistry.

[21]  I. Hollander,et al.  Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. , 2008, Bioconjugate chemistry.

[22]  Irwin Hollander,et al.  Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.

[23]  Damon L. Meyer,et al.  Dipeptide-based highly potent doxorubicin antibody conjugates. , 2006, Bioorganic & medicinal chemistry letters.

[24]  Damon L. Meyer,et al.  Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. , 2007, Bioorganic & medicinal chemistry letters.

[25]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[26]  R. Panchal,et al.  Novel therapeutic strategies to selectively kill cancer cells. , 1998, Biochemical pharmacology.

[27]  Jennifer B. Webster,et al.  Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. , 2006, Protein engineering, design & selection : PEDS.

[28]  A. Wahl,et al.  In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  K. Khandke,et al.  CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin , 2009 .

[30]  Yelena Kovtun,et al.  Semisynthetic maytansine analogues for the targeted treatment of cancer. , 2006, Journal of medicinal chemistry.

[31]  P. Senter,et al.  Novel peptide linkers for highly potent antibody-auristatin conjugate. , 2008, Bioconjugate chemistry.

[32]  D. Boger,et al.  CBI Prodrug Analogs of CC-1065 and the Duocarmycins , 1999 .

[33]  J. Larrick,et al.  Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue. , 2006, Bioorganic & medicinal chemistry.

[34]  S. Winstein,et al.  Neighboring Carbon and Hydrogen. Li. Dienones from Ar1[UNK]-3 Participation. Isolation and Behavior of Spiro(2,5)octa-1,4-diene-3-one , 1963 .

[35]  Damon L. Meyer,et al.  Contribution of linker stability to the activities of anticancer immunoconjugates. , 2008, Bioconjugate chemistry.

[36]  A. Wahl,et al.  Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. , 2002, The Journal of organic chemistry.

[37]  Bonnie F. Sloane,et al.  Unraveling the role of proteases in cancer. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[38]  X. Geng,et al.  Tumor-specific novel taxoid-monoclonal antibody conjugates. , 2004, Journal of medicinal chemistry.

[39]  Prodrug Strategies in Anticancer Chemotherapy , 2008, ChemMedChem.

[40]  A. Tolcher,et al.  Technology Insight: cytotoxic drug immunoconjugates for cancer therapy , 2007, Nature Clinical Practice Oncology.

[41]  R. Lutz,et al.  Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.

[42]  T. Chittenden,et al.  Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. , 2006, Cancer research.

[43]  K. Gomi,et al.  Synthesis and antitumor activity of duocarmycin derivatives. , 1995, Chemical & pharmaceutical bulletin.